ClinicalTrials.gg
CompletedNCT00383149Updated Mar 10, 2016Results posted

A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer

A Phase 2 interventional study of Ixabepilone and Cetuximab in Metastatic Pancreatic Cancer, sponsored by R-Pharm. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-10.

Sponsored by R-Pharm · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
58
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 21 studies testing cetuximab in Pancreatic Neoplasms — 1 open to participants now, 1 under way, none of them phase 3. Cetuximab · Pancreatic Neoplasms.

Enrollment
10th of 21
58 · median 44
Started
2007
with 2 others
Phase 2
12 of 21
none open now
Registered
10th of 21
by date

Among the 21 studies testing cetuximab in Pancreatic Neoplasms, this one is the 10th largest by enrollment, is one of 3 that started in 2007, is one of 12 in phase 2, and was the 10th registered.

Pancreatic Neoplasms

3,902 studies on the registry are indexed under Pancreatic Neoplasms; 1,004 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

1 of the 21 studies testing cetuximab in Pancreatic Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 741 Pancreatic Neoplasms studies recruiting now, 475 (64%) set no upper age limit and 152 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing cetuximab in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this clinical research study is to learn if ixabepilone plus cetuximab improves survival when given as 1st line chemotherapy in subjects with metastatic pancreatic cancer compared to historical data. The safety of this combination treatment will also be studied.

03

Conditions studied

  • Metastatic Pancreatic Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Histologic or cytologic diagnosis of pancreatic adenocarcinoma (locally advanced disease that is not surgically resectable, or distant disease)
  • Participants must have as per (RECIST) guidelines
  • Participants must not have received prior chemotherapy, immunotherapy or chemoradiotherapy for advanced pancreas cancer
  • performance status (KPS) of 70-100
  • Adequate hematologic, hepatic and renal function
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    Ixabepilone plus Cetuximab

    All participants were administered ixabepilone at a starting dose of 32 mg/m\^2 as a 3-hour intravenous (IV) infusion every 3 weeks. In addition, all participants were administered an initial dose of cetuximab (400 mg/m\^2 IV over 2 hours) followed by a weekly lower dose (250 mg/m\^2 IV over 1 hour).

    Drug: Ixabepilone · Drug: Cetuximab

Interventions

  • Intravenous Infusion (IV), 32 mg/m\^2 every 21 days.

    Also known as: IXEMPRA®, Erbitux®, BMS-247550, BMS-564717

  • Initial dose of 400 mg/m\^2 intravenous (IV) over 2 hours) followed by a weekly lower dose of 250 mg/m\^2 IV over 1 hour.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Surviving at 6 Months

    The percentage of participants surviving at 6 months was defined as the number of treated participants who had not died prior to 6 months from the date of their first dose divided by the total number of treated participants.

    Time frame: From time of first dose of study drug through 6 months

Secondary outcomes

  1. Best Overall Tumor Response

    Tumor response was assessed according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR)= disappearance of all non-target lesions, Partial Response (PR)= at least 30% reduction in the sum of the longest diameter (LD) of all target lesions in reference to the baseline sum LD; Stable Disease (SD)= neither PR nor progressive disease (PD) criteria were met; PD = at least 20% increase in the sum of the LD of all target lesions, taking as reference the smallest sum LD recorded at or following baseline.

    Time frame: From time of first dose of study until 16.49 months (longest period for participant between first dose and documented disease progression)

  2. Percentage of Participants With Objective Tumor Response

    Percentage of participants with objective tumor response was determined by the number of participants with PR or CR divided by the total number of response-evaluable participants. Tumor response was assessed according RECIST criteria: PR=at least 30% reduction in the sum of the LD of all target lesions in reference to the baseline sum LD, CR=Disappearance of all non-target lesions.

    Time frame: From time of first dose of study until 16.49 months (longest period for participant between first dose and documented disease progression

  3. Median Progression Free Survival Time

    Progression-Free Survival (PFS) time was defined as the time, in months, from the first dosing date until the date of disease progression or death from any cause.

    Time frame: From time of first dose of study until 16.49 months (longest period for participant between first dose and documented disease progression

  4. Median Overall Survival Time

    Overall survival time was defined as the time in months from the first dosing date to the date of death.

    Time frame: From the first dosing date until death (last reported death was 21 months after first dose).

  5. Median Duration of Response

    Duration of response was defined as the number of months from when measurement criteria were first met for CR or PR (whichever was recorded first) until the first date of disease progression or death. Complete Response (CR)= disappearance of all non-target lesions, Partial Response (PR)= at least 30% reduction in the sum of the longest diameter (LD) of all target lesions in reference to the baseline sum LD.

    Time frame: From first date recorded for CR or PR until the first date of disease progression or death (last participant with tumor response progressed 6.5 months after documented response).

  6. Median Time to Response

    Time to response was defined as the number of weeks from first dose of study therapy (ixabepilone or cetuximab) until measurement criteria were first met for PR or CR, whichever status was recorded first. Complete Response (CR)= disappearance of all non-target lesions, Partial Response (PR)= at least 30% reduction in the sum of the longest diameter (LD) of all target lesions in reference to the baseline sum LD.

    Time frame: Time from first dose of study therapy until first date of PR or CR. Maximum time to response was 19 months.

  7. Number of Participants With Death Within 30 Days of Last Dose, Any Serious Adverse Event (SAE), Any Adverse Event (AE) Leading to Discontinuation (DC), or Any Treatment-related AEs By Common Terminology Criteria Version 3.0 (CTC v3) Grade (Gr)

    AE=any new untoward medical occurrence or worsening of a pre-existing medical condition not necessarily having a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization/causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, or is an important medical event.

    Time frame: From the time of first dose of study drug to ≤30 days after the end of the last dose of study drug or until resolution of study drug-related toxicity.

  8. Number of Participants With Most Common Treatment-related Nonhematologic AE (>25%) By CTC v3 Grade (Gr)

    AE=any new untoward medical occurrence or worsening of a pre-existing medical condition not necessarily having a causal relationship with this treatment. Acneform rash and peripheral neuropathy were captured by multiple MedDRA preferred terms. Acneform rash included rash, rash pustular, and rash pruritic preferred terms. Peripheral neuropathy included neuromuscular toxicity, peripheral motor neuropathy, and peripheral sensorimotor neuropathy preferred terms.

    Time frame: From the time of first dose of study drug to ≤30 days after the end of the last dose of study drug or until resolution of study drug-related toxicity.

  9. Number of Participants With Hematology, Liver Function, and Renal Laboratory Abnormalities By CTC v3 Grade (Gr)

    Laboratory results were graded according to CTC v 3.0. Hematology laboratory evaluations included absolute neutrophil count (ANC), white blood cell count (WBC), platelets (PLT), and hemoglobin (HGB). Liver function laboratory evaluations included alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, and total bilirubin. Renal function laboratory evaluation included creatinine.

    Time frame: From the time of first dose of study drug to ≤30 days after the end of the last dose of study drug or until resolution of study drug-related toxicity.

  10. Number of Participants With Dose Reduction, Dose Delay, or Dose Interruption

    Dose reduction of ixabepilone and/or cetuximab due to toxicity was permitted for participants deriving benefit from therapy. Each drug could be dose modified independently of the others. Participants unable to start a cycle due to unacceptable toxicity related to ixabepilone or cetuximab could have therapy delayed for up to 4 weeks. If toxicities prevented the administration of ixabepilone or cetuximab therapy, participants continued receiving the other therapy as scheduled. A dose interruption for ixabepilone or cetuximab was defined as any interruption during the infusion period.

    Time frame: From the first dosing date of Cycle 1 until the last dosing date of the last cycle. Last dosing cycle for a participant was Cycle 21.

  11. Percentage of Participants With Baseline Epidermal Growth Factor Receptor (EGFR) Tumor Expression

    EGFR expression was evaluated by means of an immunohistochemical assay using tumor tissue collected prior to receiving first dose.

    Time frame: Baseline

  12. Change From Baseline in FHSI-8 Total Score by Time-point

    The FHSI-8 includes eight items representing pancreatic-related symptoms; each symptom is rated by participants on a scale of from 0 to 4. The FHSI-8 total score ranges in value from 0 to 32, with higher scores representing fewer symptoms and lower scores representing more symptoms. Scoring of the FHSI-8 was to be conducted according to the Functional Assessment of Chronic Illness Therapy (FACIT) manual. The symptom assessment was to include treated participants who had baseline measurement and at least one on-study measurement of FHSI-8 questionnaire.

    Time frame: Baseline, Week 3, Week 6, Week 9, Week 12, Week 12, Week 18, Week 24 and every 3 weeks through end of study (participant death/withdrawal from study)

07

Results

Posted Oct 19, 2010
Limitations and caveats
Study CA163-116 was completed; however, the combination tested in this trial failed to meet the primary objective to demonstrate a 6-month survival rate greater than 50% in participants with metastatic pancreatic cancer.

Participant flow

Participant flow — Overall Study
MilestoneIxabepilone + Cetuximab
Started54
Completed0
Not completed54
Withdrew: Adverse event not related to study drug3
Withdrew: Death2
Withdrew: Disease progression38
Withdrew: Lost to follow-up1
Withdrew: Other1
Withdrew: Study drug toxicity4
Withdrew: Request to discontinue treatment4
Withdrew: Participant withdrew consent1

Outcome measures

PrimaryPercentage of Participants Surviving at 6 Months

The percentage of participants surviving at 6 months was defined as the number of treated participants who had not died prior to 6 months from the date of their first dose divided by the total number of treated participants.

Time frame:
From time of first dose of study drug through 6 months
Reported as:
Number · percentage of participants
Percentage of Participants Surviving at 6 Months
percentage of participantsIxabepilone + Cetuximab
Percentage of Participants Surviving at 6 Months57.4 (43.2 to 70.8)
SecondaryBest Overall Tumor Response

Tumor response was assessed according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR)= disappearance of all non-target lesions, Partial Response (PR)= at least 30% reduction in the sum of the longest diameter (LD) of all target lesions in reference to the baseline sum LD; Stable Disease (SD)= neither PR nor progressive disease (PD) criteria were met; PD = at least 20% increase in the sum of the LD of all target lesions, taking as reference the smallest sum LD recorded at or following baseline.

Time frame:
From time of first dose of study until 16.49 months (longest period for participant between first dose and documented disease progression)
Reported as:
Number · participants
Best Overall Tumor Response
participantsIxabepilone + Cetuximab
Participants with Complete Response0
Participants with Partial Response4
Participants with Stable Disease24
Participants with Progressive Disease2
Participants with Response Unable to be Determined1
SecondaryPercentage of Participants With Objective Tumor Response

Percentage of participants with objective tumor response was determined by the number of participants with PR or CR divided by the total number of response-evaluable participants. Tumor response was assessed according RECIST criteria: PR=at least 30% reduction in the sum of the LD of all target lesions in reference to the baseline sum LD, CR=Disappearance of all non-target lesions.

Time frame:
From time of first dose of study until 16.49 months (longest period for participant between first dose and documented disease progression
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Tumor Response
percentage of participantsIxabepilone + Cetuximab
Percentage of Participants With Objective Tumor Response12.9 (3.6 to 29.8)
SecondaryMedian Progression Free Survival Time

Progression-Free Survival (PFS) time was defined as the time, in months, from the first dosing date until the date of disease progression or death from any cause.

Time frame:
From time of first dose of study until 16.49 months (longest period for participant between first dose and documented disease progression
Reported as:
Median · months
Median Progression Free Survival Time
monthsIxabepilone + Cetuximab
Median Progression Free Survival Time3.9 (2.6 to 4.4)
SecondaryMedian Overall Survival Time

Overall survival time was defined as the time in months from the first dosing date to the date of death.

Time frame:
From the first dosing date until death (last reported death was 21 months after first dose).
Reported as:
Median · months
Median Overall Survival Time
monthsIxabepilone + Cetuximab
Median Overall Survival Time7.6 (5.5 to 12.2)
SecondaryMedian Duration of Response

Duration of response was defined as the number of months from when measurement criteria were first met for CR or PR (whichever was recorded first) until the first date of disease progression or death. Complete Response (CR)= disappearance of all non-target lesions, Partial Response (PR)= at least 30% reduction in the sum of the longest diameter (LD) of all target lesions in reference to the baseline sum LD.

Time frame:
From first date recorded for CR or PR until the first date of disease progression or death (last participant with tumor response progressed 6.5 months after documented response).
Reported as:
Median · months
Median Duration of Response
monthsIxabepilone + Cetuximab
Median Duration of Response5.7 (2.8 to 6.3)
SecondaryMedian Time to Response

Time to response was defined as the number of weeks from first dose of study therapy (ixabepilone or cetuximab) until measurement criteria were first met for PR or CR, whichever status was recorded first. Complete Response (CR)= disappearance of all non-target lesions, Partial Response (PR)= at least 30% reduction in the sum of the longest diameter (LD) of all target lesions in reference to the baseline sum LD.

Time frame:
Time from first dose of study therapy until first date of PR or CR. Maximum time to response was 19 months.
Reported as:
Median · weeks
Median Time to Response
weeksIxabepilone + Cetuximab
Median Time to Response8.8 (5.1 to 19.0)
SecondaryNumber of Participants With Death Within 30 Days of Last Dose, Any Serious Adverse Event (SAE), Any Adverse Event (AE) Leading to Discontinuation (DC), or Any Treatment-related AEs By Common Terminology Criteria Version 3.0 (CTC v3) Grade (Gr)

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition not necessarily having a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization/causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, or is an important medical event.

Time frame:
From the time of first dose of study drug to ≤30 days after the end of the last dose of study drug or until resolution of study drug-related toxicity.
Reported as:
Number · participants
Number of Participants With Death Within 30 Days of Last Dose, Any Serious Adverse Event (SAE), Any Adverse Event (AE) Leading to Discontinuation (DC), or Any Treatment-related AEs By Common Terminology Criteria Version 3.0 (CTC v3) Grade (Gr)
participantsIxabepilone + Cetuximab
All deaths within 30 days of last dose7
Any SAE32
Gr 2 (moderate) AE leading to DC2
Gr 3 (severe) AE leading to DC9
Gr 4 (life-threatening) AE leading to DC3
All AEs leading to DC14
Gr 1 (mild) treatment-related AE4
Gr 2 (moderate) treatment-related AE13
Gr 3 (severe) treatment-related AE25
Gr 4 (life-threatening) treatment-related AE10
Gr 5 (death) treatment-related AE1
All treatment-related AEs53
SecondaryNumber of Participants With Most Common Treatment-related Nonhematologic AE (>25%) By CTC v3 Grade (Gr)

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition not necessarily having a causal relationship with this treatment. Acneform rash and peripheral neuropathy were captured by multiple MedDRA preferred terms. Acneform rash included rash, rash pustular, and rash pruritic preferred terms. Peripheral neuropathy included neuromuscular toxicity, peripheral motor neuropathy, and peripheral sensorimotor neuropathy preferred terms.

Time frame:
From the time of first dose of study drug to ≤30 days after the end of the last dose of study drug or until resolution of study drug-related toxicity.
Reported as:
Number · participants
Number of Participants With Most Common Treatment-related Nonhematologic AE (>25%) By CTC v3 Grade (Gr)
participantsIxabepilone + Cetuximab
Gr 1 (mild) acneform rash21
Gr 2 (moderate) acneform rash13
Gr 3 (severe) acneform rash1
All acneform rash35
Gr 1 (mild) fatigue8
Gr 2 (moderate) fatigue13
Gr 3 (severe) fatigue8
Gr 4 (life-threatening) fatigue1
All fatigue30
Gr 1 (mild) alopecia13
Gr 2 (moderate) alopecia12
All alopecia25
Gr 1 (mild) nausea13
Gr 2 (moderate) nausea6
Gr 3 (severe) nausea3
All nausea22
Gr 1 (mild) diarrhea11
Gr 2 (moderate) diarrhea4
Gr 3 (severe) diarrhea1
Gr 4 (life-threatening) diarrhea2
All diarrhea18
Gr 1 (mild) vomiting12
Gr 2 (moderate) vomiting2
Gr 3 (severe) vomiting3
All vomiting17
Gr 1 (mild) peripheral neuropathy12
Gr 2 (moderate) peripheral neuropathy1
Gr 3 (severe) peripheral neuropathy3
All peripheral neuropathy16
Gr 1 (mild) hypomagnesemia7
Gr 2 (moderate) hypomagnesemia4
Gr 3 (severe) hypomagnesemia1
Gr 4 (life-threatening) hypomagnesemia3
All hypomagnesemia15
SecondaryNumber of Participants With Hematology, Liver Function, and Renal Laboratory Abnormalities By CTC v3 Grade (Gr)

Laboratory results were graded according to CTC v 3.0. Hematology laboratory evaluations included absolute neutrophil count (ANC), white blood cell count (WBC), platelets (PLT), and hemoglobin (HGB). Liver function laboratory evaluations included alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, and total bilirubin. Renal function laboratory evaluation included creatinine.

Time frame:
From the time of first dose of study drug to ≤30 days after the end of the last dose of study drug or until resolution of study drug-related toxicity.
Reported as:
Number · participants
Number of Participants With Hematology, Liver Function, and Renal Laboratory Abnormalities By CTC v3 Grade (Gr)
participantsIxabepilone + Cetuximab
Gr 0 (no abnormality) WBC, n=5112
Gr 1 (mild) WBC, n=519
Gr 2 (moderate) WBC, n=519
Gr 3 (severe) WBC, n=5117
Gr 4 (life-threatening) WBC, n=514
Gr 1-4 WBC, n=5139
Gr 3-4 WBC, n=5121
Gr 0 (no abnormality) ANC, n=5012
Gr 1 (mild) ANC, n=508
Gr 2 (moderate) ANC, n=5012
Gr 3 (severe) ANC, n=5010
Gr 4 (life-threatening) ANC, n=508
Gr 1-4 ANC, n=5038
Gr 3-4 ANC, n=5118
Gr 0 (no abnormality) platelet count, n=5129
Gr 1 (mild) platelet count, n=5118
Gr 2 (moderate) platelet count, n=514
Gr 1-4 platelet count, n=512
Gr 0 (no abnormality) HGB, n=513
Gr 1 (mild) HGB, n=5128
Gr 2 (moderate) HGB, n=5118
Gr 3 (severe) HGB, n=512
Gr 1-4 HGB, n=5148
Gr 3-4 HGB, n=512
Gr 0 (no abnormality) ALT, n=4631
Gr 1 (mild) ALT, n=4610
Gr 2 (moderate) ALT, n=463
Gr 3 (severe) ALT, n=462
Gr 1-4 ALT, n=4615
Gr 3-4 ALT, n=462
Gr 0 (no abnormality) AST, n=4728
Gr 1 (mild) AST, n=4717
Gr 3 (severe) AST, n=472
Gr 1-4 AST, n=4719
Gr 3-4 AST, n=472
Gr 0 (no abnormality) alkaline phosphatase, n=4718
Gr 1 (mild) alkaline phosphatase, n=4720
Gr 2 (moderate) alkaline phosphatase, n=475
Gr 3 (severe) alkaline phosphatase, n=474
Gr 1-4 alkaline phosphatase, n=4729
Gr 3-4 alkaline phosphatase, n=474
Gr 0 (no abnormality) total bilirubin, n=4842
Gr 1 (mild) total bilirubin, n=481
Gr 2 (moderate) total bilirubin, n=481
Gr 3 (severe) total bilirubin, n=484
Gr 1-4 total bilirubin, n=486
Gr 3-4 total bilirubin, n=484
Gr 0 (no abnormality) creatinine, n=4845
Gr 1 (mild) creatinine, n=483
Gr 1-4 creatinine, n=483
SecondaryNumber of Participants With Dose Reduction, Dose Delay, or Dose Interruption

Dose reduction of ixabepilone and/or cetuximab due to toxicity was permitted for participants deriving benefit from therapy. Each drug could be dose modified independently of the others. Participants unable to start a cycle due to unacceptable toxicity related to ixabepilone or cetuximab could have therapy delayed for up to 4 weeks. If toxicities prevented the administration of ixabepilone or cetuximab therapy, participants continued receiving the other therapy as scheduled. A dose interruption for ixabepilone or cetuximab was defined as any interruption during the infusion period.

Time frame:
From the first dosing date of Cycle 1 until the last dosing date of the last cycle. Last dosing cycle for a participant was Cycle 21.

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Baseline Epidermal Growth Factor Receptor (EGFR) Tumor Expression

EGFR expression was evaluated by means of an immunohistochemical assay using tumor tissue collected prior to receiving first dose.

Time frame:
Baseline

No measurements were reported for this outcome.

SecondaryChange From Baseline in FHSI-8 Total Score by Time-point

The FHSI-8 includes eight items representing pancreatic-related symptoms; each symptom is rated by participants on a scale of from 0 to 4. The FHSI-8 total score ranges in value from 0 to 32, with higher scores representing fewer symptoms and lower scores representing more symptoms. Scoring of the FHSI-8 was to be conducted according to the Functional Assessment of Chronic Illness Therapy (FACIT) manual. The symptom assessment was to include treated participants who had baseline measurement and at least one on-study measurement of FHSI-8 questionnaire.

Time frame:
Baseline, Week 3, Week 6, Week 9, Week 12, Week 12, Week 18, Week 24 and every 3 weeks through end of study (participant death/withdrawal from study)

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ixabepilone + Cetuximab—32/54 (59.3%)49/54 (90.7%)
Most frequent serious events
Showing 10 of 51
Most frequent serious events
EventIxabepilone + Cetuximab
HYPOTENSIONVascular disorders6/54
PANCREATIC CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)6/54
DEHYDRATIONMetabolism and nutrition disorders5/54
VOMITINGGastrointestinal disorders4/54
HYPERSENSITIVITYImmune system disorders3/54
NAUSEAGastrointestinal disorders3/54
PYREXIAGeneral disorders3/54
ATRIAL FIBRILLATIONCardiac disorders2/54
DEEP VEIN THROMBOSISVascular disorders2/54
DIARRHOEAGastrointestinal disorders2/54
Most frequent other events
Showing 10 of 59
Most frequent other events
EventIxabepilone + Cetuximab
FATIGUEGeneral disorders34/54
DERMATITIS ACNEIFORMSkin and subcutaneous tissue disorders29/54
NAUSEAGastrointestinal disorders25/54
ALOPECIASkin and subcutaneous tissue disorders25/54
DIARRHOEAGastrointestinal disorders22/54
CONSTIPATIONGastrointestinal disorders20/54
VOMITINGGastrointestinal disorders18/54
ABDOMINAL PAINGastrointestinal disorders17/54
ANOREXIAMetabolism and nutrition disorders17/54
HYPOMAGNESAEMIAMetabolism and nutrition disorders17/54

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ixabepilone + Cetuximab
Median63.0 (47.0 to 84.0)
Age, Customized
Age, Customized(participants)Ixabepilone + Cetuximab
Age Greater than, equal to 65 years22
Age less than 65 years32
Sex: Female, Male
Sex: Female, Male(Participants)Ixabepilone + Cetuximab
Female19
Male35
08

Study locations

9 sites
  • Georgetn Univ Lombardi Can Ctr
    Washington, District of Columbia 20007, United States
  • Mayo Clinic Jacksonville
    Jacksonville, Florida 32224, United States
  • University Of Miami
    Miami, Florida 33136, United States
  • University Of Michigan
    Ann Arbor, Michigan 48109, United States
  • Wayne State University
    Detroit, Michigan 48201, United States
  • Ellis Fischel Cancer Center
    Columbia, Missouri 65203, United States
  • Cancer Centers Of The Carolinas
    Greenville, South Carolina 29615, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
  • West Virginia University
    Morgantown, West Virginia 26506, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2010, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2006
First posted
Oct 2, 2006
Start
Jan 2007
Primary completionActual
Jun 2009
CompletionActual
Jun 2009
Results first posted
Oct 19, 2010
Last update
Mar 10, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00383149
Lead sponsor
R-Pharm
Responsible party
Sponsor
First posted
Oct 2, 2006
Start date
Jan 2007
Primary completion
Jun 2009
Completion
Jun 2009
Results posted
Oct 19, 2010
Last update
Mar 10, 2016

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ixabepilone · Cetuximab

Start the discussion